CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1α Pathway.
CDCA2
HIF-1a
apoptosis
proliferation
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
11
2019
accepted:
16
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Prostate cancer (PCa) is a major serious malignant tumor and is commonly diagnosed in older men. Identification of novel cancer-related genes in PCa is important for understanding its tumorigenesis mechanism and developing new therapies against PCa. Here, we used RNA sequencing to identify the specific genes, which are upregulated in PCa cell lines and tissues. The cell division cycle associated protein (CDCA) family, which plays a critical role in cell division and proliferation, is upregulated in the PCa cell lines of our RNA-Sequencing data. Moreover, we found that
Identifiants
pubmed: 32509575
doi: 10.3389/fonc.2020.00725
pmc: PMC7248370
doi:
Types de publication
Journal Article
Langues
eng
Pagination
725Informations de copyright
Copyright © 2020 Zhang, Cheng, Zhang, Bai, Jin, Guo, Huang, Li, Wang, Shu, Yuan and Ying.
Références
ACS Chem Biol. 2007 Aug 17;2(8):561-71
pubmed: 17708671
BMC Cancer. 2012 Jul 28;12:321
pubmed: 22839099
Biochem Biophys Res Commun. 2018 Feb 5;496(2):482-489
pubmed: 29326043
Onco Targets Ther. 2018 Feb 20;11:891-901
pubmed: 29503564
Oncotarget. 2017 Jul 11;8(28):45459-45469
pubmed: 28525372
J Biol Chem. 2009 Apr 10;284(15):10004-12
pubmed: 19211554
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Int J Oncol. 2016 Oct;49(4):1385-93
pubmed: 27499128
Cancer Cell. 2005 Nov;8(5):393-406
pubmed: 16286247
Br J Cancer. 2016 Oct 11;115(8):929-939
pubmed: 27599042
Cold Spring Harb Perspect Biol. 2010 May;2(5):a000661
pubmed: 20452955
PLoS One. 2014 Aug 14;9(8):e105104
pubmed: 25122487
Oncotarget. 2018 Jan 9;9(6):6977-6992
pubmed: 29467944
J Biol Chem. 2006 Jun 2;281(22):15215-26
pubmed: 16565084
Mol Med Rep. 2018 Jan;17(1):1507-1512
pubmed: 29257222
J Cell Biol. 2006 Feb 27;172(5):679-92
pubmed: 16492807
BMC Cancer. 2019 Jun 13;19(1):576
pubmed: 31196027
BJU Int. 2010 Jan;105(1):8-13
pubmed: 19889065
Proc Natl Acad Sci U S A. 2014 May 27;111(21):7531-6
pubmed: 24821806
Front Immunol. 2014 May 06;5:191
pubmed: 24834066
PLoS One. 2013;8(2):e56381
pubmed: 23418564
Nat Commun. 2017 Jan 16;8:14048
pubmed: 28091603
Nat Cell Biol. 2014 Oct;16(10):962-71, 1-8
pubmed: 25218637
Dev Cell. 2011 Aug 16;21(2):328-42
pubmed: 21820363
Cancer Res. 2010 Dec 1;70(23):9671-81
pubmed: 21098706
Oncotarget. 2017 Mar 21;8(12):19768-19779
pubmed: 28423619
Mol Endocrinol. 2011 Apr;25(4):621-34
pubmed: 21330406
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Oncogene. 2005 Feb 24;24(9):1533-41
pubmed: 15592497
Nat Commun. 2019 Jan 17;10(1):278
pubmed: 30655535
Int J Cancer. 2012 Dec 15;131(12):2785-94
pubmed: 22505354
J Biol Chem. 2002 Nov 15;277(46):43799-808
pubmed: 12228247
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Cancer Res. 2008 Jan 1;68(1):172-80
pubmed: 18172309
Mol Carcinog. 2015 Jul;54(7):554-65
pubmed: 24347249
Expert Rev Mol Med. 2009 Aug 27;11:e26
pubmed: 19709449
Adv Exp Med Biol. 2014;773:401-14
pubmed: 24563358
Cancer Res. 2014 Feb 1;74(3):954-63
pubmed: 24351292
Am J Transl Res. 2015 Apr 15;7(4):710-22
pubmed: 26064439
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Nat Commun. 2018 Nov 21;9(1):4900
pubmed: 30464211
Oncotarget. 2017 May 2;8(18):30008-30018
pubmed: 28404905
J Biol Chem. 2001 Oct 19;276(42):38527-35
pubmed: 11486006
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5566-E5575
pubmed: 29844188
Clin Cancer Res. 2012 Apr 1;18(7):2108-14
pubmed: 22465832